Claims for Patent: 10,538,590

Summary for Patent: 10,538,590

Title:	Photosensitizing antibody-fluorophore conjugates
Abstract:	The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm.sup.-2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
Inventor(s):	Kobayashi; Hisataka (Laurel, MD), Choyke; Peter (Rockville, MD)
Assignee:	The United States of America, as represented by the Secretary, Dept. of Health and Human Services (Bethesda, MD)
Application Number:	13/972,532
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,538,590
Patent Claims:	1. A phototoxic pharmaceutical composition for the treatment of a cancer expressing HER1, HER2 or PMSA, comprising: a phototoxic conjugate comprising an IR700 molecule conjugated to an antibody that binds to a cell surface protein, wherein the antibody is selected from the group consisting of Panitumumab, Trastuzumab, and J591 or an antigen binding fragment thereof; and a pharmaceutical carrier, wherein the phototoxic conjugate exhibits phototoxicity to kill cells expressing the cell surface protein bound by the antibody or antigen binding fragment of the conjugate. 2. The pharmaceutical composition of claim 1, wherein the antibody is Panitumumab. 3. The pharmaceutical composition of claim 2, wherein there are about three IR700 molecules per Panitumumab molecule. 4. The pharmaceutical composition of claim 1, wherein the antibody is Trastuzumab. 5. The pharmaceutical composition of claim 4, wherein there are about three IR700 molecules per Trastuzumab molecule. 6. The pharmaceutical composition of claim 1, wherein the antibody is J591. 7. The pharmaceutical composition of claim 6, wherein there are about two IR700 molecules per J591 molecule. 8. The pharmaceutical composition of claim 1, wherein the composition comprises physiological saline. 9. The pharmaceutical of claim 1, wherein the composition comprises water. 10. The pharmaceutical composition of claim 1, wherein the antibody fragment is selected from a Fab fragment, a Fab' fragment, a F(ab)'.sub.2 fragment, a single chain Fv (scFv) or a disulfide stabilized Fv (dsFv). 11. The pharmaceutical composition of claim 1, wherein the cell is a tumor cell.

Details for Patent 10,538,590

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2030-07-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2030-07-09
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2030-07-09